Linqiang Lai, Yanji Wang, Jiangle Jiang, Dengfa Yang, Jinying Wu, Liangjun Xie, Jiahao Wu, Ruolan Mao, Dengke Zhang, Xiangxue Wang, Wenlong Ming, Jianfei Tu
The multimodal model consistently predicted the high-risk recurrence phenotype across multiple centers. This phenotype may serve as a pragmatic indicator of poor DFS to guide earlier individualized treatment decisions, including adjuvant therapy and intensified surveillance, in stage IA NSCLC.
OBJECTIVES: To develop and validate a preoperative multimodal model that predicts a high-risk recurrence phenotype indicative of poor disease-free survival (DFS), in order to stratify patients with stage IA non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: This retrospective multicenter study enrolled 342 stage IA NSCLC patients from three independent centers. The high-risk recurrence phenotype (indicative of poor DFS) was defined by postoperative pathology as the presence of spread through air spaces (STAS), lymphovascular invasion (LVI), a predominant solid/micropapillary/complex glandular pattern, or a > 5% solid/micropapillary component. Deep learning features were extracted from preoperative biopsy whole-slide images (WSI) using the UNI foundation model, and CT morphological and textural features were extracted from preoperative chest CT. An early-fusion multimodal model integrating clinical, radiomics, and pathomics features was developed and evaluated with five-fold cross-validation. The Kaplan-Meier method with log-rank tests was used to assess associations between the model-predicted risk and DFS. Logistic regression identified clinical predictors of high-risk pathology. Model interpretability and clinical utility were examined with SHapley Additive exPlanations (SHAP) and calibration analysis, respectively.
RESULTS: The multimodal model achieved higher discriminative performance than each single-modality model in both the internal and external test sets. In the internal test set, it yielded an AUC of 0.76 (95% CI 0.58-0.90); in external validation, AUCs were 0.69 (95% CI 0.55-0.82) in Center 2 and 0.86 (95% CI 0.74-0.96) in Center 3. Multivariable analysis identified solid tumor density as the only independent predictor (OR = 5.13, 95% CI 1.53-17.24; P = 0.008). Model-stratified high-risk patients showed significantly inferior DFS in both the training (2-year DFS 78% vs. 99%; log-rank P < 0.0001) and external (3-year DFS 86% vs. 100%; log-rank P = 0.003) cohorts.
CONCLUSION: The multimodal model consistently predicted the high-risk recurrence phenotype across multiple centers. This phenotype may serve as a pragmatic indicator of poor DFS to guide earlier individualized treatment decisions, including adjuvant therapy and intensified surveillance, in stage IA NSCLC.